Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil

doi:10.3748/wjg.v27.i2.208

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7520)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

568

WORD

298

HTML

3707

Figures (1-1)

416

Tables (1-3)

361

Sum=5350

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

651

Download

1519

Sum=2170

Jan 14, 2021 (publication date) through Nov 3, 2024

Times Cited of This Article

Times Cited (14)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Observational Study

World J Gastroenterol. Jan 14, 2021; 27(2): 208-223
Published online Jan 14, 2021. doi: 10.3748/wjg.v27.i2.208

Table 2 Montreal classification and activity scores at enrollment by inflammatory bowel diseases type and geographic region

CD classification	CD patients (n = 264)	Southeast (n = 196)	South (n = 34)	Northeast/Midwest (n = 34)
Location¹
L1-ileal	67 (25.4)	50 (25.5)	10 (29.4)	7 (20.6)
L2-colonic	42 (15.9)	26 (13.3)	5 (14.7)	11 (32.4)
L3-ileocolonic	150 (56.8)	116 (59.2)	18 (52.9)	16 (47.1)
L4-upper GI tract disease	17 (6.4)	11 (5.6)	2 (5.9)	4 (11.8)
Behavior
B1-Nonstricturing/nonpenetrating	58 (22.0)	33 (16.8)	9 (26.5)	16 (47.1)
B2-Stricturing	110 (41.7)	89 (45.4)	14 (41.2)	7 (20.6)
B3-Penetrating	91 (34.5)	70 (35.7)	10 (29.4)	11 (32.4)
Perianal disease	105 (39.8)	87 (44.4)	12 (35.3)	6 (17.6)
HBI score	2.0 [0-37]	2.0 [0-37]	2.0 [0-17]	3.5 [0-12]
Missing	34	32	0	2
CDAI	137.0 [-25-495]	141.0 [-25-495]	NA	93.0 [-22-292]
Missing	187	137	34	16
Active CD²	118 (44.7)	89 (45.4)	13 (38.2)	16 (47.0)
HBI ≥ 8 or CDAI ≥ 220	46 (17.4)	UNK	UNK	UNK
Fecal calprotectin > 200 μg/g	40 (15.2)	UNK	UNK	UNK
Colonoscopy result suggestive of disease activity during the previous year	69 (26.1)	UNK	UNK	UNK
UC classification	UC patients (n = 143)	Southeast (n = 94)	South (n = 21)	Northeast/Midwest (n = 28)
Extension
E1-distal UC	43 (30.1)	27 (28.7)	8 (38.1)	8 (28.6)
E2-left-sided	26 (18.2)	12 (12.8)	2 (9.5)	12 (42.9)
E3-pancolitis	74 (51.7)	55 (58.5)	11 (52.4)	8 (28.6)
Severity
S0-asymptomatic	57 (39.9)	36 (38.3)	9 (42.9)	12 (42.9)
S1-mild UC	32 (22.4)	25 (26.6)	3 (14.3)	4 (14.3)
S2-moderate UC	40 (28.0)	25 (26.6)	7 (33.3)	8 (28.6)
S3-severe UC	14 (9.8)	8 (8.5)	2 (9.5)	4 (14.3)
Mayo endoscopic subscore (n = 71)
Normal	16 (22.5)	9 (19.1)	1 (12.5)	6 (37.5)
Mild disease	18 (25.4)	13 (27.7)	2 (25.0)	3 (18.8)
Moderate disease	28 (39.4)	20 (42.6)	3 (37.5)	5 (31.3)
Severe disease	9 (12.7)	5 (10.6)	2 (25.0)	2 (12.5)
Missing	72	47	13	12
Total Mayo score	2.0 [0.0-10.0]	3.0 [0.0-9.0]	2.5 [0.0-10.0]	2.0 [0.0-8.0]
Missing	72	47	13	12
Partial Mayo score	1.0 [0.0-9.0]	1.5 [0.0-9.0]	1.0 [0.0-9.0]	1.5 [0.0-8.0]
Active UC²	36 (25.2)	19 (20.2)	5 (23.8)	12 (42.9)

Data are shown as n (%) or median [range].

¹More than one possible option: L4 includes isolated upper gastrointestinal (GI) tract disease or upper GI tract disease combined with L1, L2 or L3.

²Active disease at enrollment was defined as presenting Harvey-Bradshaw index ≥ 8 or Crohn’s disease activity index ≥ 220 or fecal calprotectin > 200 mg/g or colonoscopy suggestive of inadequate control during the previous year (for Crohn’s disease patients) and partial Mayo score ≥ 5 (for ulcerative colitis patients). CD: Crohn’s disease; CDAI: Crohn’s disease activity index; HBI: Harvey-Bradshaw index; UC: Ulcerative colitis; UNK: Unknown; GI: Gastrointestinal.

Citation: Zaltman C, Parra RS, Sassaki LY, Santana GO, Ferrari MLA, Miszputen SJ, Amarante HMBS, Kaiser Junior RL, Flores C, Catapani WR, Parente JML, Bafutto M, Ramos O, Gonçalves CD, Guimaraes IM, da Rocha JJR, Feitosa MR, Feres O, Saad-Hossne R, Penna FGC, Cunha PFS, Gomes TN, Nones RB, Faria MAG, Parente MPPD, Scotton AS, Caratin RF, Senra J, Chebli JM. Real-world disease activity and sociodemographic, clinical and treatment characteristics of moderate-to-severe inflammatory bowel disease in Brazil. World J Gastroenterol 2021; 27(2): 208-223
URL: https://www.wjgnet.com/1007-9327/full/v27/i2/208.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i2.208